- Home
- BFRG vs ICCM Comparison
BFRG vs ICCM Comparison
Compare BFRG & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFRG | ICCM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 8.3M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BFRG | ICCM |
|---|---|---|
| Price | $0.49 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | ★ 1.1M | 150.1K |
| Earning Date | 11-13-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,670.00 | N/A |
| Revenue This Year | $568.55 | $27.11 |
| Revenue Next Year | $573.08 | $104.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.49 | N/A |
| 52 Week Low | $0.43 | $0.13 |
| 52 Week High | $1.96 | $9.54 |
Technical Indicators
Market Signals| Indicator | BFRG | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 19.13 |
| Support Level | $0.43 | $0.22 |
| Resistance Level | $0.69 | $2.50 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 19.84 | 22.56 |
Price Performance
Historical ComparisonAbout BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.